Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.

罗斯威尔癌症研究所的网络领导学术参与站点资助。

• 批准号: 9031741
• 负责人: SHASHIKANT LELE
• 金额: $ 61.6万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-06 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9031741
• 关键词: Area; Beds; Blood; Breast; Buffaloes; Canada; Cancer Biology; Cancer Center Support Grant; Cancer Hospital; Cancer Patient; Caring; Clinic; Clinic Activity; Clinical; Clinical Data; Clinical Research; Clinics and Hospitals; Comprehensive Cancer Center; Conduct Clinical Trials; Connecticut; County; Cutaneous; Data; Disease; Doctor of Philosophy; Educational process of instructing; Enrollment; Family; Floor; Flow Cytometry; Gamma Knife Radiosurgery; Geographic Locations; Grant; Head and Neck Cancer; Health; Health Professional; Heart; Hematologic Neoplasms; Hospitals; Housing; Human Resources; Image Cytometry; Infusion procedures; Institutes; Institution; Intensity-Modulated Radiotherapy; Investigational Drugs; Laboratories; Lead; Life; Linear Accelerator Radiotherapy Systems; Malignant - descriptor; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of brain; Marrow; Medical; Medicine; Mission; Molecular; Monitor; National Cancer Institute; New York; Nursing Staff; Oncologic Nursing; Oncology Nurse; Operative Surgical Procedures; Pathology; Patient Care; Patient advocacy; Patients; Patients' Rooms; Pediatric Oncology; Pennsylvania; Phase; Physicians' Offices; Population; Preparation; Prevention education; Protocols documentation; Quality of life; Radiation; Radiation Oncology; Radiology Specialty; Research; Research Personnel; Resource Sharing; Resources; Roswell Park Cancer Institute; Services; Site; Specialist; Specimen; Supervision; System; Techniques; Therapeutic; Therapeutic Human Experimentation; Thoracic Oncology; Time; Transplantation; anticancer research; authority; cancer prevention; cancer therapy; clinical care; design; experience; improved; inter-institutional; melanoma; metropolitan; multidisciplinary; novel therapeutics; oncology; oncology service; organizational structure; phase 3 study; prognostic; programs; sample collection; sarcoma; square foot; symposium; tomography

DESCRIPTION (provided by applicant): The Roswell Park Cancer Institute has had a long tradition of contributing to the national cooperative groups over many decades. Those contributions have been scientific, administrative, and participatory (over 1200 patients have been enrolled in cooperative group trials over the last 5 years). Contributions have been consistent and numerous over the years. This application summarizes the intent of its 4 Co-PIs (Dr. Levine/Dr. Adjei/Dr. Lele/Dr. Singh) and the membership of RPCI to sustain its commitment to the many strengths inherent to cooperative group research: therapeutic advances; a better understanding of the biology of cancer; cancer prevention; means to improve the quality of life of cancer patients; piloting of new drugs and radiology and radiation and surgical techniques; establishing the relevance of new cellular and molecular advances to the predictive, prognostic, and therapeutic approaches to patients; and the advancement of patient advocacy. Investigators at RPCI and its supporting staff fully recognize the essential importance of the timely and accurate submission of data and specimens to achieve these aims.

描述（由申请人提供）：罗斯威尔帕克癌症研究所几十年来一直有着为国家合作团体做出贡献的悠久传统。这些贡献具有科学性、管理性和参与性（过去 5 年已有 1200 多名患者参加了合作小组试验）。多年来，贡献始终如一且数量众多。本申请总结了 4 位 Co-PI（Levine 博士/Adjei 博士/Lele 博士/Singh 博士）和 RPCI 成员的意图，以维持其对合作小组研究固有的许多优势的承诺：治疗进展；更好地了解癌症的生物学；癌症预防；改善癌症患者生活质量的手段；新药、放射学、放射线和外科技术的试点；建立新的细胞和分子进展与患者预测、预后和治疗方法的相关性；以及患者倡导的进步。 RPCI 的研究人员及其支持人员充分认识到及时、准确地提交数据和样本对于实现这些目标的重要性。